Skip to main content
SpringerLink
Log in

Adverse Events in Cancer Immunotherapy

  • Chapter
  • First Online:
Immunotherapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 995))

  • 5464 Accesses

Abstract

Cancer immunotherapy has resulted in durable responses in patients with metastatic disease, unseen with traditional chemotherapy. Several therapies have been approved by the Food and Drug Administration for the treatment of various cancers, including: immune checkpoint inhibitors, cytokines - interleukin 2 (IL-2) and interferon alpha (IFN), and the cancer vaccine sipuleucel-T. These therapies upregulate the immune system to enhance antitumor responses. As a consequence, they can cause inflammatory and immune-related adverse events that can affect one or more organs, can be serious, and on occasion lifethreatening. The management of these adverse events is complex, and requires a multidisciplinary approach involving not only oncologists, but also other internal medicine specialists, to ensure prompt diagnosis and optimal management of these complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.

    Article  CAS  PubMed  Google Scholar 

  2. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7.

    Article  CAS  PubMed  Google Scholar 

  3. Chen WW, Razak ARA, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs). J Clin Oncol. 2016;34(15).

    Google Scholar 

  4. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 2015;34(43):5411–7.

    Google Scholar 

  5. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48.

    Article  CAS  PubMed  Google Scholar 

  6. Johnson DB, Friedman DL, Berry EG, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res. 2015;3(5):464–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hammers HJ, Plimack ER, Sternberg C, McDermott DF, Larkin JMG, Ravaud A, Rini BI, Sharma P, Bhagavatheeswaran P, Gagnier P, Motzer R. CheckMate 214: a phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2015;33(15 Suppl 1).

    Google Scholar 

  8. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.

    Article  CAS  PubMed  Google Scholar 

  9. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015;13(1):211.

    Google Scholar 

  10. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254–63.

    Article  CAS  PubMed  Google Scholar 

  11. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

    Article  PubMed  CAS  Google Scholar 

  12. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.

    Article  PubMed  Google Scholar 

  13. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, K.-. investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.

    Article  CAS  PubMed  Google Scholar 

  14. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.

    Article  CAS  PubMed  Google Scholar 

  15. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.

    Article  CAS  PubMed  Google Scholar 

  16. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2015;2(2):1–7.

    Google Scholar 

  17. Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol. 2015;30(10):e89–91.

    Article  PubMed  Google Scholar 

  18. Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol. 2016;96(2):259–60.

    Article  CAS  PubMed  Google Scholar 

  19. Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol. 2015;151(7):797–9.

    Article  PubMed  Google Scholar 

  20. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–12.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Totonchy MB, Ezaldein HH, Ko CJ, Choi JN. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol. 2016;152(5):590–2.

    Article  PubMed  Google Scholar 

  22. Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, Bagaria S, Jambusaria-Pahlajani A. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3(1):18–22.

    Article  PubMed  Google Scholar 

  23. Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S, Kwong BY. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43(4):339–46.

    Article  PubMed  Google Scholar 

  24. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121–8.

    Article  CAS  PubMed  Google Scholar 

  26. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O’Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18.

    Article  CAS  PubMed  Google Scholar 

  27. Gupta A, De Felice KM, Loftus EV, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406–17.

    Article  CAS  PubMed  Google Scholar 

  28. Pernot S, Ramtohul T, Taieb J. Checkpoint inhibitors and gastrointestinal immune-related adverse events. Curr Opin Oncol. 2016;28(4):284–9.

    Article  CAS  Google Scholar 

  29. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28(6):593–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–75.

    Article  CAS  PubMed  Google Scholar 

  31. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37(5):499–507.

    Article  CAS  PubMed  Google Scholar 

  32. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29–38.

    Article  CAS  PubMed  Google Scholar 

  33. Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2015;19(1):82–92.

    Article  CAS  Google Scholar 

  34. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016;28(4):278–87.

    Article  CAS  PubMed  Google Scholar 

  36. Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents. Cancer J. 2016;22(2):121–9.

    Article  CAS  PubMed  Google Scholar 

  37. Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, Ibrahim N. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs. 2013;31(4):1071–7.

    Article  CAS  PubMed  Google Scholar 

  38. Tabchi S, Messier C, Blais N. Immune-mediated respiratory adverse events of checkpoint inhibitors. Curr Opin Oncol. 2016;28(4):269–77.

    Article  CAS  PubMed  Google Scholar 

  39. Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30(17):e156–9.

    Article  PubMed  Google Scholar 

  40. Tirumani SH, Ramaiya NH, Keraliya A, Bailey N, Ott PA, Hodi FS, Nishino M. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–86.

    Article  CAS  PubMed  Google Scholar 

  42. Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, Le D, Bingham 3rd CO. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2016;76(1):43–50.

    Article  PubMed  Google Scholar 

  43. Calabrese L, Velcheti V. Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases. Ann Rheum Dis. 2017;76(1):1–3.

    Google Scholar 

  44. Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ, Jacobs JF, Schalken JA, Oosterwijk E, van Eenennaam H, Boots AM. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169–78.

    Article  CAS  PubMed  Google Scholar 

  45. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009;7:35.

    Article  CAS  Google Scholar 

  46. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13(6):668–77.

    Article  CAS  PubMed  Google Scholar 

  47. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.

    PubMed  PubMed Central  Google Scholar 

  48. Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med. 2011;365(18):1747–8.

    Article  CAS  PubMed  Google Scholar 

  49. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211–2.

    Article  CAS  PubMed  Google Scholar 

  50. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014;6(230): 230ra245.

    Google Scholar 

  51. Kong YC, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front Immunol. 2014;5:206.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164(2):303–7.

    Article  CAS  PubMed  Google Scholar 

  53. Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, Martins B, Andreia R, Viana JF, Crespo F, Vasconcelos C, Ferreira C, Vicente AM. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet. 2004;12(8):620–6.

    Article  CAS  PubMed  Google Scholar 

  54. Lee YH, Bae SC, Kim JH, Song GG. Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z Rheumatol. 2015;74(3):230–9.

    Article  CAS  PubMed  Google Scholar 

  55. Lee YH, Kim JH, Seo YH, Choi SJ, Ji JD, Song GG. CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis. Hum Immunol. 2014;75(5):414–21.

    Article  CAS  PubMed  Google Scholar 

  56. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus. 2009;18(1):9–15.

    Article  CAS  PubMed  Google Scholar 

  57. Li G, Shi F, Liu J, Li Y. The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis. Diagn Pathol. 2014;9:157.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Liu JL, Zhang FY, Liang YH, Xiao FL, Zhang SQ, Cheng YL, Yuan CD, Chen QP, Yang S, Zhang XJ. Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis. J Eur Acad Dermatol Venereol. 2009;23(4):425–32.

    Article  PubMed  Google Scholar 

  59. Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev. 2008;223:143–55.

    Article  CAS  PubMed  Google Scholar 

  60. Wu J, Zhang L, Zhou Y. The association between CTLA-4 (+49 A/G) polymorphism and susceptibility to ankylosing spondylitis: a meta-analysis. Int J Rheum Dis. 2015.

    Google Scholar 

  61. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, Pamer EG, Wolchok JD. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, Francois H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–74.

    Article  CAS  PubMed  Google Scholar 

  63. U.S. Food and Drug Administration. Yervoy: risk evaluation and mitigation strategy (REMS). 2016. http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm249435.pdf. Accessed 5 Oct 2016.

  64. Bagley SJ, Kosteva JA, Evans TL, Langer CJ. Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. Cancer Treatment Commun. 2016;6:20–3.

    Article  Google Scholar 

  65. Batacchi Z, Alarcon-Casas Wright L. Hyperthyroidism followed by worsening primary hypothyroidism in a patient treated with ipilimumab and pembrolizumab. Thyroid. 2015;25:A215.

    Google Scholar 

  66. Bostwick AD, Salama AK, Hanks BA. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer. 2015;3:19.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Chia PL, John T. Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC). J Immunother. 2016;39(5):202–4.

    Article  CAS  PubMed  Google Scholar 

  68. Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler. 2015;21(5):670.

    Article  PubMed  Google Scholar 

  69. Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):e55–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, Thomas M, Baumelou A, Rouvier P. Kidney injuries related to ipilimumab. Invest New Drugs. 2014;32(4):769–73.

    Article  CAS  PubMed  Google Scholar 

  71. Kamil F, Cohen M, Kumta N, Wan D. Ipilimumab-induced colitis in a patient with ulcerative colitis and lung cancer. Am J Gastroenterol. 2013;108:S404.

    Google Scholar 

  72. Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2(1):35.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Lau KHV, Kumar A, Yang I, Nowak R. A case of myasthenia gravis exacerbation in a patient with melanoma treated with pembrolizumab. Neurology 2016;86(16 Suppl 1).

    Google Scholar 

  74. Maul LV, Weichenthal M, Kahler KC, Hauschild A. Successful anti-PD-1 antibody treatment in a metastatic melanoma patient with known severe autoimmune disease. J Immunother. 2016;39(4):188–90.

    Article  CAS  PubMed  Google Scholar 

  75. Menzies AM, Johnson DB, Ramanujam S, Atkinson V, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). J Clin Oncol. 2016;34(15).

    Google Scholar 

  76. Narita T, Oiso N, Taketomo Y, Okahashi K, Yamauchi K, Sato M, Uchida S, Matsuda H, Kawada A. Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol. 2015;43(2):210–4.

    Article  PubMed  Google Scholar 

  77. Pedersen M, Andersen R, Norgaard P, Jacobsen S, Thielsen P, Thor Straten P, Svane IM. Successful treatment with Ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother. 2014;63(12):1341–6.

    Article  CAS  PubMed  Google Scholar 

  78. Plachouri KM, Mohr M, Sunderkotter C, Weishaupt C. Induction of muscular sarcoidosis in a metastastic melanoma patient treated with ipilimumab. J German Soc Dermatol. 2012;10(11):861.

    Google Scholar 

  79. Sahuquillo-Torralba A, Ballester-Sanchez R, Pujol-Marco C, Botella-Estrada R. Pembrolizumab: a new drug that can induce exacerbations of psoriasis. [Spanish]. Actas Dermosifiliogr. 2016;107(3):264–6.

    Article  CAS  PubMed  Google Scholar 

  80. Weishaupt C, Mohr M, Sunderkotter C. Muscular sarcoidosis in a metastastic melanoma patient treated with ipilimumab. J German Soc Dermatol. 2012;10(9):683.

    Google Scholar 

  81. Zmeili O, Samantray J. Anti-CTLA-4 antibody therapy causing autoimmune hypophysitis in a patient with a longstanding history of hashimotos's thyroiditis. Endocrine Rev 2013;1.

    Google Scholar 

  82. Hotte S, Waldron T, Canil C, Winquist E. Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. Can Urol Assoc J. 2007;1(1):27–38.

    PubMed  PubMed Central  Google Scholar 

  83. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9(4):694–704.

    Article  CAS  PubMed  Google Scholar 

  84. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 2002;16(11 Suppl 13):11–20.

    Google Scholar 

  85. Schwartzentruber D. Interleukin-2: clinical applications. Principles of administration and management of side effects. In: Rosenberg SA, editor. Principles and practice of the biologic therapy of cancer Philadelphia: Lippincott Williams & Wilkins; 2000. p. 32–50.

    Google Scholar 

  86. Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol. 1988;8(6):426–36.

    Article  CAS  PubMed  Google Scholar 

  87. Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, Atkins MB. High dose interleukin-2 (Aldesleukin)—expert consensus on best management practices-2014. J Immunother Cancer. 2014;2(1):26.

    Article  Google Scholar 

  88. Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, DiBisceglie AM, Hoofnagle JH, Yolles P, Rosenberg SA, Lotze MT. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol. 1989;7(12):1852–62.

    Article  CAS  PubMed  Google Scholar 

  89. Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. J Clin Oncol. 1990;8(11):1839–46.

    Article  CAS  PubMed  Google Scholar 

  90. Sikora S, Sarnsonov M, Dookeran K, Edington H, Lotze M. Peripheral nerve entrapment: an unusual adverse event with high-dose interleukin-2 therapy. Ann Oncol. 1996;7(5):535–6.

    Article  CAS  PubMed  Google Scholar 

  91. Sarna G, Figlin R, Pertcheck M, Altrock B, Kradjian S. Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results. J Biol Response Mod. 1989;8(1):16–24.

    CAS  PubMed  Google Scholar 

  92. MacFarlane MP, Yang JC, Guleria AS, White Jr RL, Seipp CA, Einhorn JH, White DE, Rosenberg SA. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer. 1995;75(4):1030–7.

    Article  CAS  PubMed  Google Scholar 

  93. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med. 1990;322(14):959–65.

    Article  CAS  PubMed  Google Scholar 

  94. Oleksowicz L, Strack M, Dutcher JP, Sussman I, Caliendo G, Sparano J, Wiernik PH. A distinct coagulopathy associated with interleukin-2 therapy. Br J Haematol. 1994;88(4):892–4.

    Article  CAS  PubMed  Google Scholar 

  95. Lee SH, Baig M, Rusciano V, Dutcher JP. Novel management of pruritus in patients treated with IL-2 for metastatic renal cell carcinoma and malignant melanoma. J Immunother. 2010;33(9):1010–3.

    Article  CAS  PubMed  Google Scholar 

  96. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, Rosenberg SA, Schwartzentruber DJ. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol. 1995;18(4):272–8.

    Article  CAS  PubMed  Google Scholar 

  97. Quan Jr W, Ramirez M, Taylor C, Quan F, Vinogradov M, Walker P. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over. Cancer Biother Radiopharm. 2005;20(1):11–5.

    Article  CAS  PubMed  Google Scholar 

  98. Payne R, Glenn L, Hoen H, Richards B, Smith 2nd JW, Lufkin R, Crocenzi TS, Urba WJ, Curti BD. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer. 2014;2:13.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Dutcher J, Atkins MB, Margolin K, Weiss G, Clark J, Sosman J, Logan T, Aronson F, Mier J. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol. 2001;18(3):209–19.

    Article  CAS  PubMed  Google Scholar 

  100. Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27(6):423–31.

    Article  CAS  PubMed  Google Scholar 

  101. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002;20(17):3703–18.

    Article  CAS  PubMed  Google Scholar 

  102. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986;4(2):234–43.

    Article  CAS  PubMed  Google Scholar 

  103. Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. Psychol Med. 2000;30(2):259–68.

    Article  CAS  PubMed  Google Scholar 

  104. Ackerman SK, Hochstein HD, Zoon K, Browne W, Rivera E, Elisberg B. Interferon fever: absence of human leukocytic pyrogen response to recombinant alpha-interferon. J Leukoc Biol. 1984;36(1):17–25.

    CAS  PubMed  Google Scholar 

  105. Dinarello CA, Bernheim HA, Duff GW, Le HV, Nagabhushan TL, Hamilton NC, Coceani F. Mechanisms of fever induced by recombinant human interferon. J Clin Invest. 1984;74(3):906–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Guillot B, Blazquez L, Bessis D, Dereure O, Guilhou JJ. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology. 2004;208(1):49–54.

    Article  CAS  PubMed  Google Scholar 

  107. Salman H, Bergman M, Bessler H, Alexandrova S, Djaldetti M. The effect of interferon on mouse myocardial capillaries: an ultrastructural study. Cancer. 1999;85(6):1375–9.

    Article  CAS  PubMed  Google Scholar 

  108. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest. 1991;99(3):557–61.

    Article  CAS  PubMed  Google Scholar 

  109. Kondo Y, Yukinaka M, Nomura M, Nakaya Y, Ito S. Early diagnosis of interferon-induced myocardial disorder in patients with chronic hepatitis C: evaluation by myocardial imaging with 123I-BMIPP. J Gastroenterol. 2000;35(2):127–35.

    Article  CAS  PubMed  Google Scholar 

  110. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dreno B, Kirkwood JM. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008;112(5):982–94.

    Article  CAS  PubMed  Google Scholar 

  111. Willson RA. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol. 2002;35(1):89–92.

    Article  CAS  PubMed  Google Scholar 

  112. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89(6–7):884–93.

    Article  CAS  PubMed  Google Scholar 

  113. Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, Kirchner H, Ganser A, Atzpodien J. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol. 1999;17(2):529–33.

    Article  CAS  PubMed  Google Scholar 

  114. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer. 2001;92(6 Suppl):1664–8.

    Article  CAS  PubMed  Google Scholar 

  115. Khakoo AY, Halushka MK, Rame JE, Rodriguez ER, Kasper EK, Judge DP. Reversible cardiomyopathy caused by administration of interferon α. Nat Clin Pract Cardiovasc Med. 2005;2(1):53–7.

    Article  PubMed  Google Scholar 

  116. FDA. Product information INTRON® A Interferon alfa-2b, recombinant. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103132s5190lbl.pdf. Accessed 25 Sept 2016

  117. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett. 2006;236(2):229–38.

    Article  CAS  PubMed  Google Scholar 

  118. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18(23):3894–903.

    Article  CAS  PubMed  Google Scholar 

  119. Solin T, Kontturi M, Pohlmann R, Vihko P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochim Biophys Acta. 1990;1048(1):72–7.

    Article  CAS  PubMed  Google Scholar 

  120. Kawalec P, Paszulewicz A, Holko P, Pilc A. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci. 2012;8(5):767–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. FDA. Approved products—PROVENGE (sipuleucel-T). 2010. http://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm210012.htm

  122. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T. 2011;36:197–202.

    PubMed  PubMed Central  Google Scholar 

  123. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–9.

    Article  CAS  PubMed  Google Scholar 

  124. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    Article  CAS  PubMed  Google Scholar 

  125. Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011;186(3):877–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to Gregory F. Pratt, from the Research Medical Library at The University of Texas MD Anderson Cancer Center for assisting in the acquisition of data.

Dr. Suarez-Almazor is the recipient of a K24 career award from the National Institute for Arthritis and Musculoskeletal and Skin Disorders (NIAMS: grant # AR053593). The funding agency had no role in the study’s design, conduct, and reporting.

Author information

Authors and Affiliations

  1. Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

    Noha Abdel-Wahab M.D., Ph.D. & Maria E. Suarez-Almazor M.D., Ph.D.

  2. Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, 71526, Egypt

    Noha Abdel-Wahab M.D., Ph.D.

  3. Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Anas Alshawa M.D.

Authors
  1. Noha Abdel-Wahab M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anas Alshawa M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria E. Suarez-Almazor M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria E. Suarez-Almazor M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, University of Texas, Houston, Texas, USA

    Aung Naing

  2. Baylor College of Medicine-Texas Children’s Hospital, Houston, Texas, USA

    Joud Hajjar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Abdel-Wahab, N., Alshawa, A., Suarez-Almazor, M.E. (2017). Adverse Events in Cancer Immunotherapy. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 995. Springer, Cham. https://doi.org/10.1007/978-3-319-53156-4_8

Download citation

Publish with us

Policies and ethics

Search

Navigation